Coppell Advisory Solutions LLC Cuts Stock Position in AstraZeneca PLC $AZN

Coppell Advisory Solutions LLC lowered its stake in AstraZeneca PLC (NASDAQ:AZN) by 27.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,117 shares of the company’s stock after selling 9,113 shares during the period. Coppell Advisory Solutions LLC’s holdings in AstraZeneca were worth $1,729,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its stake in shares of AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after buying an additional 3,224,251 shares during the last quarter. Boston Partners grew its stake in shares of AstraZeneca by 35.9% in the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after buying an additional 1,329,166 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of AstraZeneca by 5.6% in the 1st quarter. Ameriprise Financial Inc. now owns 4,942,367 shares of the company’s stock worth $364,283,000 after buying an additional 261,064 shares during the last quarter. WCM Investment Management LLC grew its stake in shares of AstraZeneca by 7.3% in the 1st quarter. WCM Investment Management LLC now owns 4,003,070 shares of the company’s stock worth $295,387,000 after buying an additional 272,537 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of AstraZeneca by 33.2% in the 1st quarter. Invesco Ltd. now owns 3,807,522 shares of the company’s stock worth $279,853,000 after buying an additional 948,659 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN stock opened at $81.70 on Monday. The stock’s 50 day simple moving average is $74.90 and its 200 day simple moving average is $72.73. The stock has a market capitalization of $253.38 billion, a PE ratio of 30.71, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $84.30.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.24 EPS. As a group, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 8th. Stockholders of record on Friday, August 8th will be given a dividend of $0.505 per share. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is presently 37.97%.

Analysts Set New Price Targets

Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.